S1 E1 - Zimmer Biomet's Rachel Ellingson on driving growth through portfolio shifts and M&A

In the inaugural episode of Ortho Innovation Talks: Zimmer Biomet, Rachel Ellingson, SVP and Chief Strategy Officer at Zimmer Biomet, shares insights into the company's growth strategy, emphasizing that growth can be achieved not only through addition - like innovation and acquisition - but also through subtraction, such as exiting lower growth, non-core businesses.

In the episode, Ellingson discusses the decision to spin off Zimmer Biomet's spine and dental businesses and the significant undertaking required to create a new public company, which required integrating and then disintegrating business segments, building corporate infrastructure, and establishing a dedicated leadership team for the new entity - a major initiative involving over 500 people and a dedicated separation management office.

Lastly, Ellingson discusses what's next in Zimmer Biomet's growth strategy, citing a balance between internal innovation and M&A and noting that the company plans to launch over 40 new products in the next 36 months, focusing on markets with at least 4% growth.

Thank you to our episode sponsor, AcuityMD for supporting this podcast. To learn more about AcuityMD, please visit http://acuitymd.com.

***

Enjoy this podcast? Follow Ortho Innovation Talks on all major podcast players: https://ortho-innovation-talks.castos.com/subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Thank you for supporting Ortho Innovation Talks!